<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00081276</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02585</org_study_id>
    <secondary_id>GOG-0126O</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <secondary_id>CDR0000360854</secondary_id>
    <nct_id>NCT00081276</nct_id>
  </id_info>
  <brief_title>3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase II Evaluation Of Triapine (NCI-Supplied Agent: NSC #663249, IND #68338) In Combination With Cisplatin (Commercially Available: NSC # 119875) In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian Or Primary Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy, such as 3-AP and cisplatin, work in different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die. Combining more than one drug may kill more&#xD;
      tumor cells. This phase II trial is studying how well giving 3-AP together with cisplatin&#xD;
      works in treating patients with recurrent or persistent platinum-resistant ovarian epithelial&#xD;
      cancer or primary peritoneal cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the antitumor activity of 3-AP and cisplatin in patients with recurrent or&#xD;
      persistent platinum-resistant ovarian epithelial or primary peritoneal cancer.&#xD;
&#xD;
      II. Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the duration of progression-free survival and overall survival in patients&#xD;
      treated with this regimen.&#xD;
&#xD;
      II. Determine the effects of prognostic variables, including initial performance status, age,&#xD;
      and mucinous (or clear cell) histology, in these patients.&#xD;
&#xD;
      OUTLINE: This is a non-randomized study.&#xD;
&#xD;
      Patients receive 3-AP IV over 2 hours on days 1-4 and cisplatin IV over 1 hour on days 2 and&#xD;
      3. Courses repeat every 21 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 23-48 patients will be accrued for this study within 13 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and duration of objective response assessed using RECIST criteria</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of observed adverse effects assessed using CTCAE version 3.0</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of progression-free survival</measure>
    <time_frame>From study entry until disease recurrence, death or date of last contact, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall survival</measure>
    <time_frame>From study entry to death or date of last contact, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic variables (e.g., initial performance status, age, and mucinous [or clear cell] histology)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <condition>Recurrent Ovarian Epithelial Cancer</condition>
  <condition>Stage III Ovarian Epithelial Cancer</condition>
  <condition>Stage IV Ovarian Epithelial Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (triapine and cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 3-AP IV over 2 hours on days 1-4 and cisplatin IV over 1 hour on days 2 and 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triapine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (triapine and cisplatin)</arm_group_label>
    <other_name>3-AP</other_name>
    <other_name>OCX-191</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (triapine and cisplatin)</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (triapine and cisplatin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial or primary peritoneal cancer&#xD;
&#xD;
               -  Recurrent or persistent disease&#xD;
&#xD;
          -  At least 1 unidimensionally measurable target lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Outside a previously irradiated field&#xD;
&#xD;
          -  Received 1 prior platinum-based chemotherapy regimen (e.g., carboplatin, cisplatin, or&#xD;
             other organoplatinum compound) for primary disease&#xD;
&#xD;
               -  Initial treatment may have included high-dose, consolidation, or extended therapy&#xD;
                  after surgical or non-surgical assessment&#xD;
&#xD;
          -  Considered platinum resistant or refractory, according to 1 of the following criteria:&#xD;
&#xD;
               -  Treatment-free interval of less than 6 months after platinum-based therapy&#xD;
&#xD;
               -  Disease progression during platinum-based therapy&#xD;
&#xD;
          -  Ineligible for any higher priority GOG protocol&#xD;
&#xD;
          -  Performance status - GOG 0-2 (for patients who received 1 prior treatment regimen)&#xD;
&#xD;
          -  Performance status - GOG 0-1 (for patients who received 2 prior treatment regimens)&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  No serious cardiac disease&#xD;
&#xD;
          -  No prior myocardial infarction&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No pulmonary disease requiring oxygen&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Neuropathy (sensory and motor) ≤ grade 1&#xD;
&#xD;
          -  No active infections requiring antibiotics&#xD;
&#xD;
          -  No hearing impairment&#xD;
&#xD;
          -  No known G6PD deficiency&#xD;
&#xD;
          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  At least 3 weeks since prior biologic or immunologic agents for malignant tumor&#xD;
&#xD;
          -  One prior non-cytotoxic regimen (e.g., monoclonal antibodies, cytokines, or&#xD;
             small-molecule inhibitors of signal transduction) allowed&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  One prior paclitaxel-containing regimen allowed&#xD;
&#xD;
          -  No prior 3-AP&#xD;
&#xD;
          -  No other prior cytotoxic chemotherapy for recurrent or persistent disease, including&#xD;
             retreatment with initial chemotherapy regimens&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  At least 1 week since prior hormonal therapy for malignant tumor&#xD;
&#xD;
          -  Concurrent hormone replacement therapy allowed&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of marrow-bearing areas&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  No prior cancer therapy that contraindicates receiving study therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lydia Usha</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

